Hookipa reports Q2 net loss $19.1M; cash $77.4M; eseba-vec Phase 2/3 trial on track for Q4 2024

HOOKIPA Pharma Inc.

2024-Q2 EPS reported -$0.38 vs consensus -$1.28 ▲ beat (+70.3%)

Net loss of $19.1M for Q2 2024 vs $18.0M in Q2 2023; revenue $1.3M down from $2.7M.
Cash, cash equivalents and restricted cash fell to $77.4M from $117.5M as of Dec 31, 2023.
Malte Peters appointed CEO and Terry Coelho as EVP & CFO effective July 22, 2024.
Eseba-vec (HB-200) AVALON-1 Phase 2/3 trial aligned with FDA; start expected Q4 2024.
Received $5M milestone from Gilead for HB-500 HIV Phase 1b first dosing; $10M from Roche for HB-700 IND.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.